SCHEMBL3244199

SCHEMBL3244199

CN(C)C1(C(NC(=O)c2ccc(Cl)cc2Cl)c2ccccc2)CCCC1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
SLC6A9 P48067 4/20 0.45
TMEM97 Q5BJF2 2/20 0.45
SIGMAR1 Q99720 2/20 0.45
ALDH1A1 P00352 2/20 0.44
GAA P10253 1/20 0.44
FLT1 P17948 1/20 0.43
FLT4 P35916 1/20 0.43
KDR P35968 1/20 0.43
GPR27 Q9NS67 1/20 0.42
P2RX7 Q99572 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HCRTR2 O43614 1/20 0.41
CYP2C19 P33261 1/20 0.40
CTSL P07711 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3237602 0.91 GPR139 (0.50) MEN1KMT2ASLC6A9ALDH1A1P2RX7
SCHEMBL3239983 0.90 UTS2R (0.42) MEN1KMT2ASLC6A9ALDH1A1FLT1
SCHEMBL3237145 0.87 AVPR2 (0.43) MEN1KMT2ASLC6A9ALDH1A1GAA
SCHEMBL3237567 0.86 SLC6A9 (0.47) SLC6A9ALDH1A1GAACYP2C19
SCHEMBL3238239 0.85 CHRM1 (0.42) MEN1KMT2ASLC6A9CYP2C19
SCHEMBL4359374 0.84 SLC6A9 (0.41) MEN1KMT2ASLC6A9NPC1RAB9A
SCHEMBL4355245 0.84 MEN1 (0.41) MEN1KMT2ASLC6A9ALDH1A1RAB9A
SCHEMBL3239515 0.84 KCNA3 (0.44) MEN1KMT2ASLC6A9CYP2C19
SCHEMBL3238379 0.84 ACLY (0.45) MEN1KMT2ASLC6A9ALDH1A1MAPT
SCHEMBL3244636 0.83 THRB (0.43) MEN1KMT2ASLC6A9MAPTCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287547-A1 Glycine Transport Inhibitors SLC18A2, SLC6A5, SLC1A2 MEN1 2501/4885KMT2A 1871/4885SLC6A9 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.